Cell and gene therapy manufacturing is characterized by complex processes and high costs, with each batch often being specific to an individual patient. The loss of even a single batch due to contamination or other issues can be devastating, both financially and for patient care. This highlights the critical need for reliable and rapid microbiological monitoring methods, such as Biofluorescent Particle Counters (BFPC), to efficiently measure sterility and reduce risk.